![Annalisa Cavalli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Annalisa Cavalli has a current job as Vice President-Operations at BMG Pharma SpA.
Posizioni attive di Annalisa Cavalli
Società | Posizione | Inizio |
---|---|---|
BMG Pharma SpA
![]() BMG Pharma SpA Household/Personal CareConsumer Non-Durables BMG Pharma SpA is a pharmaceutical company based in Milan, Italy. The Italian company specializes in the development and international partnership of bio-pharmaceutical products. The company focuses on the progress of oral care, dermatology, and dietary supplements. BMG Pharma is committed to sustainability, diversity, and inclusion in the workplace. BMG Pharma has developed the hyaluromimethic® technology, which they believe is a fundamental value. The company has registered 36 innovative products and launched 37 on the international market. Recently, BMG Pharma has signed an agreement with HTL Biotechnology for the production of the functional ingredient at the base of the patented hyaluromimethic®. The company was founded in 2011 by Marco Mastrodonato and Roberto Bianchi, with Marco Mastrodonato serving as the CEO since then. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
BMG Pharma SpA
![]() BMG Pharma SpA Household/Personal CareConsumer Non-Durables BMG Pharma SpA is a pharmaceutical company based in Milan, Italy. The Italian company specializes in the development and international partnership of bio-pharmaceutical products. The company focuses on the progress of oral care, dermatology, and dietary supplements. BMG Pharma is committed to sustainability, diversity, and inclusion in the workplace. BMG Pharma has developed the hyaluromimethic® technology, which they believe is a fundamental value. The company has registered 36 innovative products and launched 37 on the international market. Recently, BMG Pharma has signed an agreement with HTL Biotechnology for the production of the functional ingredient at the base of the patented hyaluromimethic®. The company was founded in 2011 by Marco Mastrodonato and Roberto Bianchi, with Marco Mastrodonato serving as the CEO since then. | Consumer Non-Durables |
- Borsa valori
- Insiders
- Annalisa Cavalli